FDA speeds review of "sole-source" generic competitors

FDA's Office of Generic Drugs (OGD) implemented a policy that would allow expedited review of ANDAs for "sole-source" generics that would compete with only one other approved generic. FDA already provides expedited review of the first generic competitor to an innovator drug.

According to the (see BioCentury Extra, March 3). ...